MedicinerestrictedEssential

Emtricitabine + Rilpivirine + Tenofovir

A three-drug combination tablet (emtricitabine, rilpivirine, tenofovir DF) as a complete HIV-1 regimen.

Clinical information

Common uses

initial HIV-1 therapy (viral load up to 100,000 copies/mL)
replacing a stable regimen in virologically suppressed patients

Common side effects

depressive disorders
insomnia
headache
diarrhoea, nausea and fatigue
dizziness, abnormal dreams and rash

Cautions

boxed warning: hepatitis B can flare severely after stopping
severe skin and hypersensitivity reactions including DRESS
severe depression — seek medical evaluation
kidney problems and bone density loss

Interactions

proton pump inhibitors like omeprazole — contraindicated
carbamazepine, phenytoin, phenobarbital — contraindicated
rifampin and rifapentine — contraindicated
St John's wort — contraindicated
antacids (take 2 hours before or 4 hours after)
azole antifungals and clarithromycin (raise rilpivirine levels)

Pregnancy: can be continued if already suppressed; viral load monitored closely

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, emtricitabine, rilpivirine and tenofovir disoproxil fumarate label, setid 7193c90e-456c-4cfb-8181-65a1618dae51 (accessed 2026-08-16)

Approved brands & formulations3

Brand name	Dosage form	Strength	Importer	Category
Emtricitabine + Rilpivirine + Tenofovir	Tablet	600 mg + 300 mg + 200 mg	—	restricted
Emtricitabine + Rilpivirine + Tenofovir	Tablet	200mg + 25mg + 300mg	—	restricted
Emtricitabine + Rilpivirine + Tenofovir	Tablet	200 mg+ 300 mg + 600 mg	—	restricted